The International Society for Pharmacoeconomics and Outcomes Research’s latest Value in Health contains several reports from the society’s Special Task Force on U.S. Value Assessment Frameworks.
According to a press release, the publications, which appear in a themed section of Value in Health, are the product of phase 2 of ISPOR’s Initiative on U.S. Value Assessment Frameworks.
An editorial introducing the report says the themed section contains perspectives from “key experts, representing payers, patients, academia and the pharmaceutical industry.”
“If we want to reflect value well, the challenge is not only to involve stakeholders in the process of evaluation to spot important factors not included in the QALY but also to assess and ideally quantify the trade-offs between them in a way that is transparent and consistent,” the editorial says.
To read the full editorial in Value in Health, click here.